TCR Therapy Global Market Report 2026

T-cell receptor (TCR) therapy is a type of immunotherapy that involves altering a patient's T cells to enhance their ability to identify and attack cancer cells. It is mainly used for treating cancer and aims to utilize the body's immune system to target and eliminate cancer cells.

The main types of TCR therapy include infusions, injectables, and others. Infusions typically involve steeping or soaking a substance (such as herbs, tea leaves, or flavorings) in a liquid (usually hot water) to extract its properties or flavor. They are applied to treat various conditions, including leukemia, lymphoma, myeloma, and others, and are distributed through both online and offline channels. They are utilized by several end-users, including hospital pharmacies, retail pharmacies, and specialty clinics.

Tariffs have affected the TCR therapy market by increasing the cost of imported gene-editing reagents, cell culture media, and manufacturing equipment. This has particularly impacted segments such as autologous and allogeneic TCR infusions, with North America and Europe facing higher production costs due to reliance on imported materials. Some companies are benefiting by localizing manufacturing and sourcing reagents domestically, which can reduce costs and improve supply chain resilience. Overall, tariffs have created a mixed impact, slowing adoption in some regions while driving innovation and localized production strategies.

The tcr therapy market research report is one of a series of new reports from The Business Research Company that provides tcr therapy market statistics, including tcr therapy industry global market size, regional shares, competitors with a tcr therapy market share, detailed tcr therapy market segments, market trends and opportunities, and any further data you may need to thrive in the tcr therapy industry. This tcr therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tcr therapy market size has grown exponentially in recent years. It will grow from $0.26 billion in 2025 to $0.35 billion in 2026 at a compound annual growth rate (CAGR) of 35.5%. The growth in the historic period can be attributed to early adoption of autologous tcr therapies, advancements in gene editing technologies, increasing clinical trials for cancer immunotherapy, rising incidence of hematologic malignancies, collaborations between biotech firms and hospitals.

The tcr therapy market size is expected to see exponential growth in the next few years. It will grow to $1.15 billion in 2030 at a compound annual growth rate (CAGR) of 34.8%. The growth in the forecast period can be attributed to growth in off-the-shelf allogeneic tcr therapies, integration of ai for tcr design, expansion in emerging markets, regulatory approvals for new tcr indications, advancements in combination immunotherapy approaches. Major trends in the forecast period include personalized tcr therapy development, off-the-shelf allogeneic tcr therapies, combination immunotherapy approaches, expansion of hospital and specialty clinic access, advanced tcr gene editing techniques.

The rising incidence of cancer is anticipated to drive the growth of the T-cell receptor (TCR) therapy market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, influenced by factors such as aging populations, lifestyle-related risks, genetic predispositions, and environmental exposures. The increasing number of cancer cases is expanding the global disease burden, creating a pressing need for advanced therapeutic solutions that deliver more precise and lasting clinical outcomes. TCR therapy addresses this growing medical demand by engineering T cells to specifically identify and eliminate cancer cells, offering a highly targeted immunotherapy approach for complex and treatment-resistant tumors. For example, according to the American Cancer Society, a US-based non-profit organization, the estimated new lymphoma cases rose from 89,010 in 2022 to 89,380 in 2023. Consequently, the rising incidence of cancer is fueling the growth of the TCR therapy market.

Major companies operating in the TCR therapy industry are pursuing a strategic partnership approach to deliver essential treatments to patients and secure a competitive advantage in the market. Strategic partnerships involve a process in which companies utilize each other's strengths and resources to achieve mutual benefits and success. For example, in December 2023, ImmunoScape, a US-based biotechnology company, collaborated with the Experimental Drug Development Centre (EDDC), a Singapore-based pharmaceutical company, to develop new TCR-based bispecific molecules for solid tumors. This collaboration aims to combine ImmunoScape's expertise in systems immunology and computational biology with EDDC's capabilities to advance research in this area and establish a strategic alliance that harnesses their unique strengths to accelerate the development of more accessible and potentially more effective cancer treatments.

In January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, acquired Neogene Therapeutics Inc. for $320 million. This acquisition enabled AstraZeneca to strengthen its position in the rapidly growing field of TCR-T therapy. AstraZeneca obtained access to advanced technology, valuable expertise, and a shared commitment to developing new cancer treatments, ultimately aiming to enhance the lives of patients with various types of cancer. Neogene Therapeutics Inc. is a US-based biotechnology company focused on developing next-generation, fully personalized engineered T-cell therapies for a wide range of cancers.

Major companies operating in the tcr therapy market are Immunocore Limited, Immatics N.V., Adaptimmune Therapeutics plc, Alaunos Therapeutics Inc., Zelluna Immunotherapy AS, Lion TCR Pte Ltd, TCRCure Biopharma Corp., China Immunotech Inc., Bluebird bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Precision Biosciences Inc., Cellectis S.A., Cellular Biomedicine Group Inc., Takara Bio Inc., Tessa Therapeutics, Pfizer Inc., Novartis AG, Bristol Myers Squibb Company

North America was the largest region in the TCR therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tcr therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tcr therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The TCR therapy market consists of revenues earned by entities by providing services such as genetic engineering services, quality control and assurance, clinical trial support, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The TCR therapy market also includes sales of TCR constructs, genetic modification tools, viral vectors, delivery systems, cell culture media and reagents, patient monitoring tools, and bioinformatics and data analysis tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

TCR Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tcr therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tcr therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tcr therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Infusions; Injectables; Other Product Types
• 2) By Indication: Leukemia; Lymphoma; Myeloma; Other Indication
• 3) By Distribution Channel: Online; Offline
• 4) By End-User: Hospital Pharmacy; Specialty Clinics
• Subsegments:
• 1) By Infusions: Autologous TCR Infusions; Allogeneic TCR Infusions
• 2) By Injectables: TCR-based Injectable Formulations; Injectable TCR Gene Therapies
• 3) By Other Product Types: TCR-Engineered Cell Therapies; TCR Combination Therapies with Other Immunotherapies; TCR-Based Biologics
• Companies Mentioned: Immunocore Limited; Immatics N.V.; Adaptimmune Therapeutics plc; Alaunos Therapeutics Inc.; Zelluna Immunotherapy AS; Lion TCR Pte Ltd; TCRCure Biopharma Corp.; China Immunotech Inc.; Bluebird bio Inc.; Poseida Therapeutics Inc.; Fate Therapeutics Inc.; Atara Biotherapeutics Inc.; Precision Biosciences Inc.; Cellectis S.A.; Cellular Biomedicine Group Inc.; Takara Bio Inc.; Tessa Therapeutics; Pfizer Inc.; Novartis AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.